Nuvig Therapeutics develops next‑generation immune modulators that activate endogenous regulatory pathways to restore immune tolerance without broad immunosuppression. Its lead candidate, NVG‑2089, is an engineered IgG1 Fc fragment that engages Type II Fcγ receptors, and the company’s BESTech™ platform extends this tolerogenic Fc into multi‑functional antibodies for a range of autoimmune and chronic inflammatory diseases.
Funding
$161M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1ONVFounders
Product
Problem
Existing treatments for autoimmune diseases rely on broad immunosuppression or intravenous immunoglobulin (IVIg), which carry infection risks, supply constraints, and limited therapeutic windows. These approaches do not specifically restore the body’s natural mechanisms for resolving inflammation, leaving patients with unmet needs for safe, targeted immune modulation.
Solution
Nuvig Therapeutics develops next‑generation immune modulators that activate endogenous regulatory pathways rather than suppressing immunity. Their lead candidate, NVG‑2089, is an engineered IgG1 Fc fragment that mimics the anti‑inflammatory activity of sialylated IgG by binding Type II Fcγ receptors, thereby promoting immune tolerance without compromising host defense. NVG‑2089 has demonstrated safety in Phase 1 healthy‑volunteer studies and is now in Phase 2 trials for chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP) in the U.S. and Europe. The company’s BESTech™ platform extends this Fc engineering to create bi‑ and tri‑functional antibodies that combine the tolerogenic Fc with disease‑specific antigen‑binding domains, aiming to enhance efficacy of existing anti‑inflammatory targets across a broad range of autoimmune indications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing therapies for autoimmune and chronic inflammatory diseases, as well as clinicians and healthcare systems seeking safer, mechanism‑based treatments for conditions such as CIDP and ITP.
Features
- Engineered IgG1 Fc fragment that reproduces sialylated IgG binding to Type II Fcγ receptors for targeted immune tolerance
- Clinical‑grade candidate NVG‑2089 progressing through Phase 2 trials in CIDP and ITP, with a safety profile established in Phase 1 healthy volunteers
- BESTech™ platform enabling incorporation of the tolerogenic Fc into full‑length antibodies, creating bi‑functional or tri‑functional molecules that retain target specificity while enhancing anti‑inflammatory potency
- Preclinical data showing synergistic efficacy of BESTech‑enhanced antibodies compared with wild‑type counterparts against multiple cytokine targets
- Manufacturing approach based on recombinant protein technology, avoiding the supply and safety limitations of blood‑derived IVIg products